| Scrip Code | 532649 |
|---|---|
| NSE Symbol | NECLIFE |
| MSEI Symbol | NOTLISTED |
| ISIN | INE023H01027 |
| Name of company | Nectar Lifesciences Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 14-11-2025 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 09-11-2025 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Second quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Unaudited |
| Segment Reporting | Single segment |
| Description of single segment | Pharmaceutical Business Segment. |
| Start date and time of board meeting | 14-11-2025 15:00:00 |
| End date and time of board meeting | 14-11-2025 16:30:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-07-2025 | 01-04-2025 |
| B | Date of end of reporting period | 30-09-2025 | 30-09-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 499.66 | 1,023.02 | |
| Other income | 74.07 | 106.69 | |
| Total income | 573.73 | 1,129.71 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 341.04 | 677.62 |
| (b) | Purchases of stock-in-trade | 0.00 | 0.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (5.59) | 8.02 |
| (d) | Employee benefit expense | 75.17 | 145.44 |
| (e) | Finance costs | 0.00 | 0.02 |
| (f) | Depreciation, depletion and amortisation expense | 20.41 | 72.94 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 193.32 | 380.89 |
| Total other expenses | 193.32 | 380.89 | |
| Total expenses | 624.35 | 1,284.93 | |
| 3 | Total profit before exceptional items and tax | (50.62) | (155.22) |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | (50.62) | (155.22) |
| 6 | Tax expense | ||
| 7 | Current tax | 0.00 | 0.00 |
| 8 | Deferred tax | (17.69) | (54.24) |
| 9 | Total tax expenses | (17.69) | (54.24) |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | (32.93) | (100.98) |
| 12 | Profit (loss) from discontinued operations before tax | (27,001.61) | (36,572.44) |
| 13 | Tax expense of discontinued operations | (9,433.97) | (12,749.77) |
| 14 | Net profit (loss) from discontinued operation after tax | (17,567.64) | (23,822.67) |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | (17,600.57) | (23,923.65) |
| 17 | Other comprehensive income net of taxes | 0.00 | 0.01 |
| 18 | Total Comprehensive Income for the period | (17,600.57) | (23,923.64) |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 2,242.61 | 2,242.61 | |
| Face value of equity share capital | 1 | 1 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | -0.01 | -0.05 | |
| Diluted earnings (loss) per share from continuing operations | -0.01 | -0.05 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | -7.83 | -10.62 | |
| Diluted earnings (loss) per share from discontinued operations | -7.83 | -10.62 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | -7.84 | -10.67 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | -7.84 | -10.67 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | NOTES: 1 The above financial results were reviewed by Audit Committee on November 14, 2025 and approved by the Board of Nectar Lifesciences Limited (‘Company’) in its meeting held on November 14, 2025. The statutory auditors of the Company have conducted a “Limited Review” of the above standalone and consolidated unaudited financial results/ statements for the quarter and half year ended on September 30, 2025. 2 The company is exclusively in the pharmaceutical business segment. 3 Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period. 4 The Statement of Assets and Liability is attached as Annexure 1. 5 The Statement of Cash Flow is attached as Annexure 2. 6 The Company has undertaken following transactions during the quarter: i. On July 7, 2025, the Company entered into a Business Transfer Agreement (‘BTA’) for transfer of its Active Pharmaceutical Ingredients (located at Unit 1 And Unit 2 at Derabassi, Punjab and at Unit 6, Baddi, Himachal Pradesh) (‘Pharma Business’) to Ceph Lifesciences Private Limited by way of a slump sale, on going concern basis for a total consideration of Rs. 127,000 lacs. ii. In addition, the company also entered into an agreement to transfer assets of the Company in relation to its menthol business (“Assets”) vide Asset Purchase Agreement (APA) dated July 7, 2025 to Ceph Lifesciences Private Limited for a consideration of Rs. 2,000 lacs. iii. The Company had expected to realise a consolidated amount of INR 129,000 lacs from the above transfers, subject to working capital adjustments. This proposed transfer of Pharma Business and Assets has been approved by the Shareholders of the Company by way of special resolution on August 04, 2025. The slump sale and Assets sale has been completed on November 10 2025 and accordingly after such working capital adjustments as per BTA, the final consolidated consideration has been worked out as Rs. 127,398.55 lacs including Rs. 2,000 lacs of Assets sale. iv. Consequently, In the Standalone Financial Statements, Assets and liabilities of “Pharma business” and “Assets” covered by the BTA and APA have been disclosed as held for sale and disclosed separately in the Balance Sheet as at September 30, 2025 as “Assets of discontinued operations classified as held for sale” and ”Liabilities of discontinued operations classified as held for sale” respectively. As mandated by Indian Accounting Standard (Ind AS) 105 Asset Held for Sale and Discontinued Operations (“Ind AS 105”), assets and liabilities have not been reclassified or re-presented for prior period i.e. year ended March 31, 2025. v Further the net results of “Pharma Business” and “Assets” have been disclosed separately as discontinued operation as required by Ind AS 105. Consequently, the Company’s Statement of Profit and Loss for the period ended September 30, 2025 presented pertains to its continuing operations only and for that purpose the Statement of Profit and Loss for the quarter ended June 30, 2025, September 30, 2024 has been restated accordingly. vi The closing date being subsequent to the balance sheet date, no gain/loss with respect to the Divestment have been recognized in the Statement of Profit and Loss for the quarter ended September 30, 2025. The total assets and liabilities of the Pharma business and Assets are Rs 133520.87 lacs and Rs 37186.42 lacs respectively as at September 30, 2025. vii Operations relating to the Pharma Business and Assets in respect of total income, total expenses and tax are being disclosed separately as Discontinued operations as part of the results below: S. No. Particulars Quarter Ended Half year Year Ended 30-Sep-25 30-Jun-25 30-Sep-24 30-Sep-25 30-Sep-24 31-Mar-25 Restated Restated Restated Restated Restated Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 Revenue from operations 8,827.36 27,543.15 42,215.82 36,370.51 77,629.77 1,64,865.40 2 Other income 2.56 3.00 20.71 5.56 67.46 334.75 3 Total expenses 35,831.53 37,116.98 41,334.88 72,948.51 76,208.47 1,81,057.74 4 Profit before tax (27,001.61) (9,570.83) 901.65 (36,572.44) 1,488.76 (15,857.59) 5 Tax expenses (9,433.97) (3,315.80) 318.96 (12,749.77) 547.10 (4,681.96) 6 Net profit after tax (17,567.64) (6,255.03) 582.69 (23,822.67) 941.66 (11,175.63) |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | Year ended (dd-mm-yyyy) | |
|---|---|---|
| Date of start of reporting period | 01-04-2025 | |
| Date of end of reporting period | 30-09-2025 | |
| Whether results are audited or unaudited | Unaudited | |
| Nature of report standalone or consolidated | Consolidated | |
| Assets | ||
| 1 | Non-current assets | |
| Property, plant and equipment | 2,759.11 | |
| Capital work-in-progress | ||
| Investment property | ||
| Goodwill | 0.00 | |
| Other intangible assets | 0.00 | |
| Intangible assets under development | ||
| Biological assets other than bearer plants | ||
| Investments accounted for using equity method | ||
| Non-current financial assets | ||
| Non-current investments | 23.51 | |
| Trade receivables, non-current | 697.30 | |
| Loans, non-current | 0.00 | |
| Other non-current financial assets | 50.42 | |
| Total non-current financial assets | 771.23 | |
| Deferred tax assets (net) | 18,308.11 | |
| Other non-current assets | 217.35 | |
| Total non-current assets | 22,055.80 | |
| 2 | Current assets | |
| Inventories | 298.32 | |
| Current financial asset | ||
| Current investments | 52.95 | |
| Trade receivables, current | 5,429.60 | |
| Cash and cash equivalents | 593.02 | |
| Bank balance other than cash and cash equivalents | 0.00 | |
| Loans, current | 87.48 | |
| Other current financial assets | 751.22 | |
| Total current financial assets | 6,914.27 | |
| Current tax assets (net) | ||
| Other current assets | 18,686.55 | |
| Total current assets | 25,899.14 | |
| 3 | Non-current assets classified as held for sale | 1,33,520.87 |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | |
| Total assets | 1,81,475.81 | |
| Equity and liabilities | ||
| 1 | Equity | |
| Equity attributable to owners of parent | ||
| Equity share capital | 2,242.61 | |
| Other equity | 69,444.43 | |
| Total equity attributable to owners of parent | 71,687.04 | |
| Non controlling interest | ||
| Total equity | 71,687.04 | |
| 2 | Liabilities | |
| Non-current liabilities | ||
| Non-current financial liabilities | ||
| Borrowings, non-current | 1,331.43 | |
| Trade payables, non-current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | ||
| Total Trade payable | ||
| Other non-current financial liabilities | ||
| Total non-current financial liabilities | 1,331.43 | |
| Provisions, non-current | 0.00 | |
| Deferred tax liabilities (net) | ||
| Deferred government grants, Non-current | ||
| Other non-current liabilities | ||
| Total non-current liabilities | 1,331.43 | |
| Current liabilities | ||
| Current financial liabilities | ||
| Borrowings, current | 44,553.42 | |
| Trade payables, current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | 21.99 | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 210.50 | |
| Total Trade payable | 232.49 | |
| Other current financial liabilities | 26,232.78 | |
| Total current financial liabilities | 71,018.69 | |
| Other current liabilities | 231.11 | |
| Provisions, current | 21.12 | |
| Current tax liabilities (Net) | ||
| Deferred government grants, Current | ||
| Total current liabilities | 71,270.92 | |
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | 37,186.42 |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | |
| Total liabilities | 1,09,788.77 | |
| Total equity and liabilites | 1,81,475.81 | |
| Disclosure of notes on assets and liabilities | ||
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-07-2025 | 01-04-2025 | |||||
| Date of end of reporting period | 30-09-2025 | 30-09-2025 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-07-2025 | 01-04-2025 |
| B | Date of end of reporting period | 30-09-2025 | 30-09-2025 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| Total Amount of items that will not be reclassified to profit and loss | |||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | ||
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | (0.01) |
| 5 | Total Other comprehensive income | 0.00 | 0.01 |
| Particulars | Year ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|
| A | Date of start of reporting period | 01-04-2025 | ||||
| B | Date of end of reporting period | 30-09-2025 | ||||
| C | Whether results are audited or unaudited | Unaudited | ||||
| D | Nature of report standalone or consolidated | Consolidated | ||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | (155.22) | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 3,454.77 | |||||
| Adjustments for decrease (increase) in inventories | 16,501.38 | |||||
| Adjustments for decrease (increase) in trade receivables, current | 19,568.75 | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0.00 | |||||
| Adjustments for decrease (increase) in other current assets | (2,599.41) | |||||
| Adjustments for decrease (increase) in other non-current assets | 0.00 | |||||
| Adjustments for other financial assets, non-current | 10.08 | |||||
| Adjustments for other financial assets, current | 0.00 | |||||
| Adjustments for other bank balances | 0.00 | |||||
| Adjustments for increase (decrease) in trade payables, current | (11,834.79) | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |||||
| Adjustments for increase (decrease) in other current liabilities | 61.36 | |||||
| Adjustments for increase (decrease) in other non-current liabilities | (72.08) | |||||
| Adjustments for depreciation and amortisation expense | 2,198.44 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 0.00 | |||||
| Adjustments for provisions, current | (52.32) | |||||
| Adjustments for provisions, non-current | 0.00 | |||||
| Adjustments for other financial liabilities, current | 24,765.51 | |||||
| Adjustments for other financial liabilities, non-current | 0.00 | |||||
| Adjustments for unrealised foreign exchange losses gains | 0.00 | |||||
| Adjustments for dividend income | 0.00 | |||||
| Adjustments for interest income | 37.62 | |||||
| Adjustments for share-based payments | 0.00 | |||||
| Adjustments for fair value losses (gains) | 0.00 | |||||
| Adjustments for undistributed profits of associates | 0.00 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | 32.06 | |||||
| Other adjustments to reconcile profit (loss) | (36,572.44) | |||||
| Other adjustments for non-cash items | 0.00 | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Total adjustments for reconcile profit (loss) | 15,423.69 | |||||
| Net cash flows from (used in) operations | 15,268.47 | |||||
| Dividends received | 0.00 | |||||
| Interest paid | 0.00 | |||||
| Interest received | 0.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) operating activities | 15,268.47 | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0.00 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 0.00 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 0.00 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 0.00 | |||||
| Other cash receipts from sales of interests in joint ventures | 0.00 | |||||
| Other cash payments to acquire interests in joint ventures | 0.00 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Proceeds from sales of property, plant and equipment | 32.36 | |||||
| Purchase of property, plant and equipment | 893.13 | |||||
| Proceeds from sales of investment property | 0.00 | |||||
| Purchase of investment property | 0.00 | |||||
| Proceeds from sales of intangible assets | 0.00 | |||||
| Purchase of intangible assets | 0.00 | |||||
| Proceeds from sales of intangible assets under development | 0.00 | |||||
| Purchase of intangible assets under development | 0.00 | |||||
| Proceeds from sales of goodwill | 0.00 | |||||
| Purchase of goodwill | 0.00 | |||||
| Proceeds from biological assets other than bearer plants | 0.00 | |||||
| Purchase of biological assets other than bearer plants | 0.00 | |||||
| Proceeds from government grants | 0.00 | |||||
| Proceeds from sales of other long-term assets | 0.00 | |||||
| Purchase of other long-term assets | 0.00 | |||||
| Cash advances and loans made to other parties | 0.00 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 0.00 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Dividends received | 0.04 | |||||
| Interest received | 37.58 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) investing activities | (823.15) | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |||||
| Payments from changes in ownership interests in subsidiaries | 0.00 | |||||
| Proceeds from issuing shares | 0.00 | |||||
| Proceeds from issuing other equity instruments | 0.00 | |||||
| Payments to acquire or redeem entity's shares | 0.00 | |||||
| Payments of other equity instruments | 0.00 | |||||
| Proceeds from exercise of stock options | 0.00 | |||||
| Proceeds from issuing debentures notes bonds etc | 0.00 | |||||
| Proceeds from borrowings | 0.00 | |||||
| Repayments of borrowings | 12,297.26 | |||||
| Payments of lease liabilities | 20.16 | |||||
| Dividends paid | 0.00 | |||||
| Interest paid | 3,454.77 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) financing activities | (15,772.19) | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | (1,326.87) | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 0.00 | |||||
| Net increase (decrease) in cash and cash equivalents | (1,326.87) | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 1,922.16 | |||||
| Cash and cash equivalents cash flow statement at end of period | 595.29 | |||||